Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. More Details
Flawless balance sheet and fair value.
Share Price & News
How has Calithera Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CALA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: CALA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: CALA underperformed the US Biotechs industry which returned 34.5% over the past year.
Return vs Market: CALA underperformed the US Market which returned 34.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Calithera Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StCalithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate
2 months ago | Simply Wall StCompanies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth
3 months ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Calithera Biosciences, Inc.'s (NASDAQ:CALA) Shares?
Is Calithera Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CALA ($2.98) is trading below our estimate of fair value ($6.58)
Significantly Below Fair Value: CALA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CALA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CALA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CALA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CALA is good value based on its PB Ratio (1.7x) compared to the US Biotechs industry average (4.3x).
How is Calithera Biosciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CALA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CALA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CALA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CALA's revenue (54.8% per year) is forecast to grow faster than the US market (10.5% per year).
High Growth Revenue: CALA's revenue (54.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CALA's Return on Equity is forecast to be high in 3 years time
How has Calithera Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CALA is currently unprofitable.
Growing Profit Margin: CALA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CALA is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.
Accelerating Growth: Unable to compare CALA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CALA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-37%).
Return on Equity
High ROE: CALA has a negative Return on Equity (-72.84%), as it is currently unprofitable.
How is Calithera Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: CALA's short term assets ($140.0M) exceed its short term liabilities ($19.8M).
Long Term Liabilities: CALA's short term assets ($140.0M) exceed its long term liabilities ($5.3M).
Debt to Equity History and Analysis
Debt Level: CALA is debt free.
Reducing Debt: CALA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CALA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CALA has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 27.6% each year.
What is Calithera Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CALA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CALA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CALA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CALA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CALA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Susan Molineaux (66 yo)
Dr. Susan M. Molineaux, Ph.D., serves as Director at Cyteir Therapeutics, Inc. since January 2021. She Founded Calithera Biosciences, Inc. in June 2010 and has been its Chief Executive Officer and Presiden...
CEO Compensation Analysis
Compensation vs Market: Susan's total compensation ($USD2.21M) is above average for companies of similar size in the US market ($USD950.27K).
Compensation vs Earnings: Susan's compensation has increased whilst the company is unprofitable.
|Chief Business Officer||2.08yrs||US$935.01k||0.039% |
|Chief Medical Officer||4.75yrs||US$1.24m||0.016% |
|CFO & Secretary||no data||no data||0.054% |
|Vice President of Investor Relations & Strategy||4.17yrs||no data||no data|
|Senior VP||3.33yrs||US$1.26m||0.021% |
|Head of People & Culture||no data||no data||no data|
|Senior Vice President of Drug Discovery||10.67yrs||US$959.51k||0.11% |
|Senior Vice President of Development||7.83yrs||US$446.60k||0.014% |
Experienced Management: CALA's management team is considered experienced (4.8 years average tenure).
|Independent Director||8.42yrs||US$95.47k||0% |
|Independent Director||6.17yrs||US$95.93k||0% |
|Lead Independent Director||4.08yrs||US$118.93k||0% |
|Independent Director||7.17yrs||US$85.93k||0% |
|Independent Director||5.42yrs||US$93.37k||0% |
|Director||0.58yr||no data||no data|
|Independent Director||4.5yrs||US$88.43k||0.010% |
|Independent Director||3.42yrs||US$86.45k||0% |
Experienced Board: CALA's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.2%.
Calithera Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Calithera Biosciences, Inc.
- Ticker: CALA
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$210.265m
- Shares outstanding: 70.56m
- Website: https://www.calithera.com
Number of Employees
- Calithera Biosciences, Inc.
- 343 Oyster Point Boulevard
- Suite 200
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CALA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2014|
|2CB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2014|
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/02/25 00:53|
|End of Day Share Price||2021/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.